Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RAINFALLs On Lilly's Cyramza Stomach Cancer Parade

Executive Summary

A lack of overall survival benefit in first-line stomach cancer in a Phase III trial has scuppered Eli Lilly's hopes of expanding Cyramza's use into a new and relatively empty market.

You may also be interested in...



Lilly’s Cyramza Shows Promise In First-Line NSCLC – But Not Much Room To Grow

Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?

Lonsurf Hits Phase III OS Target In Gastric Cancer Study

An improvement in overall survival seen in the Phase III TAGS study and a unique mechanism of action augurs well for Taiho/Servier's Lonsurf gaining gastric cancer as an additional indication, but future competitive pressures are likely to be intense in this therapeutic sector.

Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems

Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel